HMBEI — Pharmaceuticals, Odense
Medicines engineered with Nordic precision.
HMBEI develops treatments across cardiometabolic, immune and neurological disease from our home in Odense, Denmark — where careful science meets patients who are waiting.
What we work on
Three areas, one standard of rigor.
Cardiometabolic
Therapies for heart, metabolic and vascular conditions, built around long-term patient adherence.
Immunology
Targeted modulation of immune pathways for chronic inflammatory and autoimmune disease.
Neurology
Early-stage discovery into neurodegenerative and neuroinflammatory conditions.
In development
A pipeline built for the long run.
Cardiometabolic
Phase II
Cardiometabolic
Phase III
Immunology
Phase I
"We don't chase every disease. We choose a few, and we stay with them until the science holds up in the real world."— HMBEI Research Charter
About HMBEI
Built in Denmark, working for patients everywhere.
HMBEI is an independent pharmaceutical company headquartered in Odense — a city with a long life-science tradition. We're small enough to move carefully, and focused enough to see a compound all the way from the bench to the people who need it.
Our path
From a small lab to a full pipeline.
HMBEI is founded
Started by a small group of researchers in Odense focused on cardiometabolic disease.
First compound enters clinical trials
HMB-088 becomes our first candidate to reach human studies.
Immunology division opens
A dedicated team begins work on chronic inflammatory disease.
Neurology research begins
Early discovery work starts into neurodegenerative conditions.
12 compounds in active development
HMBEI continues to grow its pipeline across all three therapeutic areas.
What guides us
Four things we don't compromise on.
Rigor
Every result is checked twice before it's trusted once.
Care
The patient at the end of the process shapes every decision along it.
Transparency
We report what we find, including when it isn't what we hoped for.
Patience
Good medicine takes years. We plan for that, not around it.
Our home
Headquartered in Odense.
HMBEI
Rosenvej 39
5250 Odense
Denmark
Our Odense site houses research, regulatory and operations teams working alongside Denmark's wider life-science community.
Pipeline
From molecule to medicine.
Every HMBEI compound moves through the same disciplined path — discovery, preclinical safety work, then three phases of clinical study before it can reach patients.
Cardiometabolic
Discovery — Preclinical — Phase I — Phase II — Phase III
Cardiometabolic
Phase II underway
Immunology
Phase I underway
Immunology
Preclinical
Neurology
Discovery
Neurology
Discovery
Pipeline status is reviewed quarterly. For detailed data packages or partnership enquiries, please contact our team.
Research & Development
Where curiosity meets rigor.
Our research groups work close together by design — chemistry, biology and clinical teams sit in the same building in Odense, so findings move quickly between the bench and the study.
Capabilities
What happens inside HMBEI.
Recent notes
From our research team.
Rethinking dosing intervals in chronic cardiometabolic care
An internal review of how dosing schedules affect long-term adherence in our Phase II program.
Working with Nordic research hospitals on inflammatory disease
HMBEI's immunology team continues joint study design work with clinical partners across the region.
Screening for neuroprotective compounds
Our neurology group has begun early screening work as part of the HMB-317 and HMB-455 programs.
Contact
Let's talk.
Whether you're a healthcare professional, a potential partner, or just curious about our work — we'd like to hear from you.
HMBEI
5250 Odense
Denmark
09:00 – 16:00 CET
Map shown for general orientation to Odense.